OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus target price of $25.00 for the company, according to Zacks. Zacks has also assigned OptimizeRx an industry rank of 35 out of 255 based on the ratings given to related companies.

Several research firms have weighed in on OPRX. William Blair began coverage on shares of OptimizeRx in a research report on Friday, January 3rd. They issued an “outperform” rating for the company. Zacks Investment Research cut shares of OptimizeRx from a “hold” rating to a “sell” rating in a research report on Tuesday, November 5th. ValuEngine upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 4th. TheStreet cut shares of OptimizeRx from a “c” rating to a “d+” rating in a research report on Wednesday, November 20th. Finally, B. Riley lowered their price objective on shares of OptimizeRx from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, December 30th.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of OptimizeRx by 22.2% during the 2nd quarter. Vanguard Group Inc. now owns 511,060 shares of the company’s stock worth $8,279,000 after buying an additional 93,015 shares during the period. Calamos Advisors LLC grew its position in shares of OptimizeRx by 17.0% during the 3rd quarter. Calamos Advisors LLC now owns 312,764 shares of the company’s stock worth $4,529,000 after buying an additional 45,548 shares during the period. P.A.W. Capital Corp grew its position in shares of OptimizeRx by 612.5% during the 4th quarter. P.A.W. Capital Corp now owns 285,000 shares of the company’s stock worth $2,927,000 after buying an additional 245,000 shares during the period. State Street Corp grew its position in shares of OptimizeRx by 3.1% during the 4th quarter. State Street Corp now owns 238,909 shares of the company’s stock worth $2,454,000 after buying an additional 7,244 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of OptimizeRx by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 167,575 shares of the company’s stock worth $1,720,000 after buying an additional 10,278 shares during the period. Institutional investors own 58.93% of the company’s stock.

OPRX traded up $0.31 during midday trading on Wednesday, hitting $11.29. The company had a trading volume of 119,800 shares, compared to its average volume of 67,139. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.00 and a current ratio of 7.00. The company has a market capitalization of $155.59 million, a PE ratio of -125.44 and a beta of 0.31. OptimizeRx has a twelve month low of $8.63 and a twelve month high of $17.24. The firm’s 50-day simple moving average is $10.66 and its 200-day simple moving average is $12.19.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: Dividend

Get a free copy of the Zacks research report on OptimizeRx (OPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.